Navigation Links
PharmAthene Completes $6.5 Million Registered Direct Offering
Date:6/15/2011

ANNAPOLIS, Md., June 15, 2011 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that it has completed a previously announced registered direct offering raising gross proceeds for the Company of approximately $6.5 million.

Under the terms of the subscription agreements, PharmAthene sold an aggregate of 1,857,143 units to certain institutional investors for a purchase price of $3.50 per unit, with each unit consisting of one share of common stock and one warrant to purchase 0.2 of a share of common stock.  The warrants have a five year term and are immediately exercisable at an exercise price of $3.50 per share.

The net proceeds to the Company are approximately $5.8 million after placement agent fees and other offering expenses.  PharmAthene intends to use the net proceeds from the offering for general corporate purposes.

Leerink Swann served as lead placement agent and Noble Financial Capital Markets served as co-placement agent in the offering.  The securities described above were offered by PharmAthene pursuant to a registration statement previously filed and declared effective by the Securities and Exchange Commission.  Additional information and details with respect to the offering are included in a prospectus supplement that PharmAthene has filed with the Securities and Exchange Commission. The registration statement and prospectus supplement may be obtained from the Securities and Exchange Commission's website at www.sec.gov. This press release does not constitute an offer to sell, nor is it a solicitation of an offer to buy any securities, nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful. The securities may
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. PharmAthene Reports First Quarter 2011 Financial and Operating Results
2. PharmAthene to Host Year-End 2010 Earnings Conference Call and Webcast on Monday, March 28, 2011
3. PharmAthene Strengthens Scientific Leadership and Program Management for Future Growth
4. PharmAthene Receives FDA Clearance to Reinitiate Clinical Testing of Valortim®
5. PharmAthene Reports Third Quarter 2010 Financial and Operational Results
6. PharmAthene Receives Four Therapeutic Discovery Project Grants Totaling Approximately $850,000
7. PharmAthene Announces Pricing of $15 Million Public Offering
8. PharmAthene Announces Proposed Common Stock Offering
9. PharmAthene Announces $3.9 Million Registered Direct Offering
10. PharmAthene CEO To Participate on Biosecurity Panel at the 2010 BIO International Conference
11. PharmAthene Appoints Mitchel Sayare, Ph.D. to the Companys Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... Nov. 18, 2014  Asterias Biotherapeutics, Inc. (NYSE ... emerging field of regenerative medicine, today announced that ... cells) for complete cervical spinal cord injury (SCI), ... Advanced Therapies Projects to Watch" by Elsevier Business ... this significant industry honor, which represents independent validation ...
(Date:11/18/2014)... Pa. , Nov. 18, 2014  Novira Therapeutics, ... for curative treatment of chronic hepatitis B virus (HBV) ... M.D., was appointed to its Scientific Advisory Board (SAB).  ... join our SAB," said Christian S. Schade , ... of clinical development experience which will be invaluable to ...
(Date:11/17/2014)... , Nov. 17, 2014 Soligenix, Inc. ... biopharmaceutical company developing products that address unmet medical ... biodefense, announced today the formation of a Medical ... to the Company as it advances the Phase ... the treatment of cutaneous T-cell lymphoma (CTCL), a ...
(Date:11/16/2014)... November 16, 2014 James Hill and ... Filtered Fume Hoods, 3 Years Later” scheduled for Thursday, ... of 2011, Butler University surprised many in the lab ... their organic chemistry and general chemistry teaching laboratories at ... to building age and substantial growth within the chemistry ...
Breaking Biology Technology:Asterias Biotherapeutics Named as a "Top Advanced Therapies Projects to Watch" and Will Present at the Therapeutic Area Partnerships Conference 2Asterias Biotherapeutics Named as a "Top Advanced Therapies Projects to Watch" and Will Present at the Therapeutic Area Partnerships Conference 3Novira Therapeutics Announces Appointment of Brian F. Daniels, M.D., to its Scientific Advisory Board 2Novira Therapeutics Announces Appointment of Brian F. Daniels, M.D., to its Scientific Advisory Board 3Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 2Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 3Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 4Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 5Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 6Don't miss the I2SL High-Tech Talks Webinar Series Presenting: Butler University's Renovation With Filtered Fume Hoods, 3 Years Later 2Don't miss the I2SL High-Tech Talks Webinar Series Presenting: Butler University's Renovation With Filtered Fume Hoods, 3 Years Later 3
... Marketing in the United States, Trade Name Will be ... ... Limited (TSE: 4568) and Eli Lilly and Company (NYSE: LLY ) ... (NDA) for prasugrel to the U.S. Food and Drug Administration,(FDA). Prasugrel is ...
... Calif., Jan. 4 Thermage, Inc.,(Nasdaq: THRM ... the aesthetic,industry, announced today that it will present ... at The Palace Hotel in New York City. ... 2008 at 11:00,a.m. Eastern Time. Stephen J. Fanning, ...
... 2007) -- In the face of terrorism and catastrophic ... for critically injured patients are more vital than ever. ... systems -- such as the notion that it is ... first -- have rarely been subjected to rigorous scientific ...
Cached Biology Technology:Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration 2Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration 3Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration 4Triage study challenges notions of emergency medical response to disaster 2Triage study challenges notions of emergency medical response to disaster 3Triage study challenges notions of emergency medical response to disaster 4
(Date:11/7/2014)... Calif. , Nov. 7, 2014  In conjunction with ... Police Departments, The Community Foundation of the Verdugos ... DNA JUSTICE PROJECT," a $250,000 initiative to keep ... initial phase. In its first six months of existence, the ... needed evidence support for local law enforcement. "Because ...
(Date:11/6/2014)... of metastasis, yet progress in preventing and treating ... been particularly challenging to design drugs that work ... systems biology at Harvard Medical School. , ... already metastasized." , Gujral and colleagues have now ... better understand how metastasis begins. Their findings may ...
(Date:11/5/2014)... Fidel Santamaria, associate professor of biology in the ... researchers in the nation selected to receive a ... Grant for Exploratory Research (EAGER). The funding supports ... support researchers to create new technology that will ... Santamaria, complex behaviors in neuroscience are broken into ...
Breaking Biology News(10 mins):Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2Migration negation 2Migration negation 3UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3
... MA For those living with gastrointestinal disorders, such as ... through medications or dietary changes. But what if one day ... new gut free of inflamed or diseased tissues? ... and Massachusetts Institute of Technology (MIT) are hoping their new ...
... short article and photography competition were announced at an ... winning essay, by Laura Hepburn of the University of ... recent research voyage when she first saw underwater hydrothermal ... screens. These are underwater fissures that erupt volcanic gasses ...
... Switzerland)--Organizers of the 20th International AIDS Conference (AIDS 2014) ... 2014 today announced 19 major plenary presentations, focusing on ... AIDS. Plenary sessions will open each day of the conference, ... from over 200 countries. "We are excited to ...
Cached Biology News:Manufacturing a new gut to treat GI diseases 2NERC announces the winner of its first photo and essay competition 2NERC announces the winner of its first photo and essay competition 320th International AIDS Conference (AIDS 2014) plenary speakers announced 220th International AIDS Conference (AIDS 2014) plenary speakers announced 3
Immulon 1 B 1x12 Strip, flat bottom; consistent medium binding affinity for hydrophobic complexes and proteins....
The Holten Horizontal series of laminar airflow work benches offers comfort and ease of use....
...
Small bottle for hybridization 150 x 35mm...
Biology Products: